

Special Issue

Immunotherapy for Head and Neck Cancer: Biomarkers, Trials, and Transformative Outcomes

Message from the Guest Editor

Head and neck cancers (HNCs), particularly those driven by viral or environmental etiologies, present complex therapeutic challenges. Immunotherapy has emerged as a transformative treatment approach, especially in recurrent or metastatic settings, with agents like PD-1/PD-L1 inhibitors reshaping the clinical landscape. However, only a subset of patients benefit from immunotherapy, and critical questions remain regarding predictive biomarkers, resistance mechanisms, and how best to integrate immunotherapy with existing modalities. We welcome original research, clinical trial updates, and comprehensive reviews on topics including but not limited to the following:

- Biomarkers of response and resistance to immunotherapy;
- The tumor microenvironment and immune landscape of HNC;
- Real-world data and translational studies;
- Novel immunomodulatory agents and vaccine strategies;
- Outcomes and quality-of-life data in the immunotherapy era.

Our goal is to foster a deeper understanding of how immunotherapy can be optimized and personalized for patients with head and neck cancers, ultimately improving long-term outcomes.

Guest Editor

Dr. Jong Chul Park

Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA

Deadline for manuscript submissions

closed (28 February 2026)



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/245307

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncol](https://mdpi.com/journal/currentoncol)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currenocol](https://mdpi.com/journal/currenocol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)